Global Diabetic Retinopathy Market

Global Diabetic Retinopathy Market Size, Share, Growth Analysis, By Type(Proliferative Diabetic Retinopathy, and Non-proliferative diabetic retinopathy), By Management(Anti-VEGF, Intraocular Steroid Injection) - Industry Forecast 2024-2031


Report ID: SQMIG35A2516 | Region: Global | Published Date: March, 2024
Pages: 219 | Tables: 63 | Figures: 75

Global Diabetic Retinopathy Market Dynamics

Drivers

Increasing investment for healthcare infrastructure

  • The diabetic retinopathy market is experiencing notable growth driven by increased investments in healthcare infrastructure. This enhanced infrastructure contributes to improved healthcare services and accessibility. Moreover, the market is benefiting from heightened efforts by both public and private organizations to raise awareness about diabetic retinopathy. Additionally, a favorable reimbursement scenario and the presence of a population with high disposable income are facilitating the expansion of the diabetic retinopathy market. The aging demographic, coupled with evolving lifestyles, is also playing a significant role in augmenting the market's growth rate.

Increase in the number of research and development activities 

  • The growth of the diabetic retinopathy market is being driven by a surge in research and development activities. This surge is expected to create favorable opportunities for market growth. Additionally, the increasing approvals and introductions of new drugs for diabetic retinopathy will further accelerate the market's growth rate. Furthermore, heightened investments in the advancement of cutting-edge technologies and the expansion of emerging markets are expected to offer advantageous prospects for the growth of the diabetic retinopathy market during the forecast period.

Increasing prevalence of diabetes cases

  • The increasing prevalence of diabetes is a significant and fundamental driver of the diabetic retinopathy market's growth. Diabetes is a chronic metabolic disorder characterized by elevated blood sugar levels, and its global prevalence has been on the rise. This increase in diabetes cases directly correlates with a higher incidence of diabetic retinopathy, a diabetic complication affecting the eyes. Diabetic retinopathy is a serious eye condition that occurs when prolonged exposure to high blood sugar levels damages the blood vessels in the retina, leading to vision problems and, in severe cases, blindness. As the number of individuals diagnosed with diabetes continues to grow, the risk of diabetic retinopathy also increases.

Restraints

Lack of Awareness and Access about Eye Care

  • Despite the growing prevalence of diabetic retinopathy, there is a lack of awareness about the condition and the importance of regular eye examinations among diabetic patients. Limited access to eye care facilities, particularly in remote or underserved areas, hampers early detection and timely treatment.

 

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Diabetic Retinopathy Market size was valued at USD 8.30 billion in 2022 and is poised to grow from USD 8.83 billion in 2023 to USD 14.51 billion by 2031, growing at a CAGR of 6.4% during the forecast period (2024-2031).

To increase their market position, major players are focused on collaborations, partnerships, acquisitions, and other strategic operations. Industry leaders face growing competition with novel medication launches and regulatory approval of innovative management treatments, making it challenging for them to remain competitive in an ever-changing industry. However, market leaders' large investments in R&D are predicted to enhance market growth. 'Novartis AG', 'Roche Holding AG', 'Bayer AG', 'Regeneron Pharmaceuticals, Inc.', 'Allergan plc (AbbVie Inc.)', 'Carl Zeiss Meditec AG', 'Topcon Corporation', 'Nidek Co., Ltd.', 'Optos plc (Nikon Corporation)', 'Bausch Health Companies Inc.', 'Alcon Inc.', 'Santen Pharmaceutical Co., Ltd.', 'Lumenis Ltd. (XIO Group)', 'Iridex Corporation', 'Leica Microsystems (Danaher Corporation)', 'StemCells Inc. (Microbot Medical Inc.)', 'Bioptigen, Inc. (Metabolic Technologies Inc.)', 'CenterVue SpA', 'Visunex Medical Systems, Inc.', 'Clarity Medical Systems, Inc.'

Increasing Emphasis on Early Detection and Intervention: There is a growing recognition of the importance of early detection and intervention in diabetic retinopathy. The focus is shifting towards regular screening programs, awareness campaigns, and advanced imaging technologies for early diagnosis, enabling timely treatment and better management of the condition.

North America dominated the market, accounting for 37.8% of total revenue in 2022. Some of the market's drivers include the presence of modern healthcare infrastructure, favorable government activities pertaining to medication research, and the presence of substantial patient & practitioner awareness levels. One of the primary factors contributing to this region's huge share is the high market penetration of new goods such as anti-VEGF medications such as Lucentis, Avastin, and Eylea. High healthcare expenditure, increased patient knowledge of diabetes, the availability of well-established medical facilities, and a favorable reimbursement environment are some of the primary causes.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Diabetic Retinopathy Market

Product ID: SQMIG35A2516

$5,300
BUY NOW GET FREE SAMPLE